Cargando…

Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19

INTRODUCTION: Although patients with severe COVID-19 are known to be at high risk of developing thrombotic events, the effects of anticoagulation (AC) dose and duration on in-hospital mortality in critically ill patients remain poorly understood and controversial. The goal of this study was to inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoogenboom, Wouter S., Lu, Joyce Q., Musheyev, Benjamin, Borg, Lara, Janowicz, Rebeca, Pamlayne, Stacey, Hou, Wei, Duong, Tim Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769345/
https://www.ncbi.nlm.nih.gov/pubmed/35045130
http://dx.doi.org/10.1371/journal.pone.0262811
_version_ 1784635113282207744
author Hoogenboom, Wouter S.
Lu, Joyce Q.
Musheyev, Benjamin
Borg, Lara
Janowicz, Rebeca
Pamlayne, Stacey
Hou, Wei
Duong, Tim Q.
author_facet Hoogenboom, Wouter S.
Lu, Joyce Q.
Musheyev, Benjamin
Borg, Lara
Janowicz, Rebeca
Pamlayne, Stacey
Hou, Wei
Duong, Tim Q.
author_sort Hoogenboom, Wouter S.
collection PubMed
description INTRODUCTION: Although patients with severe COVID-19 are known to be at high risk of developing thrombotic events, the effects of anticoagulation (AC) dose and duration on in-hospital mortality in critically ill patients remain poorly understood and controversial. The goal of this study was to investigate survival of critically ill COVID-19 patients who received prophylactic or therapeutic dose AC and analyze the mortality rate with respect to detailed demographic and clinical characteristics. MATERIALS AND METHODS: We conducted a retrospective, observational study of critically ill COVID-19 patients admitted to the ICU at Stony Brook University Hospital in New York who received either prophylactic (n = 158) or therapeutic dose AC (n = 153). Primary outcome was in-hospital death assessed by survival analysis and covariate-adjusted Cox proportional hazard model. RESULTS: For the first 3 weeks of ICU stay, we observed similar survival curves for prophylactic and therapeutic AC groups. However, after 3 or more weeks of ICU stay, the therapeutic AC group, characterized by high incidence of acute kidney injury (AKI), had markedly higher death incidence rates with 8.6 deaths (95% CI = 6.2–11.9 deaths) per 1,000 person-days and about 5 times higher risk of death (adj. HR = 4.89, 95% CI = 1.71–14.0, p = 0.003) than the prophylactic group (2.4 deaths [95% CI = 0.9–6.3 deaths] per 1,000 person-days). Among therapeutic AC users with prolonged ICU admission, non-survivors were characterized by older males with depressed lymphocyte counts and cardiovascular disease. CONCLUSIONS: Our findings raise the possibility that prolonged use of high dose AC, independent of thrombotic events or clinical background, might be associated with higher risk of in-hospital mortality. Moreover, AKI, age, lymphocyte count, and cardiovascular disease may represent important risk factors that could help identify at-risk patients who require long-term hospitalization with therapeutic dose AC treatment.
format Online
Article
Text
id pubmed-8769345
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-87693452022-01-20 Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19 Hoogenboom, Wouter S. Lu, Joyce Q. Musheyev, Benjamin Borg, Lara Janowicz, Rebeca Pamlayne, Stacey Hou, Wei Duong, Tim Q. PLoS One Research Article INTRODUCTION: Although patients with severe COVID-19 are known to be at high risk of developing thrombotic events, the effects of anticoagulation (AC) dose and duration on in-hospital mortality in critically ill patients remain poorly understood and controversial. The goal of this study was to investigate survival of critically ill COVID-19 patients who received prophylactic or therapeutic dose AC and analyze the mortality rate with respect to detailed demographic and clinical characteristics. MATERIALS AND METHODS: We conducted a retrospective, observational study of critically ill COVID-19 patients admitted to the ICU at Stony Brook University Hospital in New York who received either prophylactic (n = 158) or therapeutic dose AC (n = 153). Primary outcome was in-hospital death assessed by survival analysis and covariate-adjusted Cox proportional hazard model. RESULTS: For the first 3 weeks of ICU stay, we observed similar survival curves for prophylactic and therapeutic AC groups. However, after 3 or more weeks of ICU stay, the therapeutic AC group, characterized by high incidence of acute kidney injury (AKI), had markedly higher death incidence rates with 8.6 deaths (95% CI = 6.2–11.9 deaths) per 1,000 person-days and about 5 times higher risk of death (adj. HR = 4.89, 95% CI = 1.71–14.0, p = 0.003) than the prophylactic group (2.4 deaths [95% CI = 0.9–6.3 deaths] per 1,000 person-days). Among therapeutic AC users with prolonged ICU admission, non-survivors were characterized by older males with depressed lymphocyte counts and cardiovascular disease. CONCLUSIONS: Our findings raise the possibility that prolonged use of high dose AC, independent of thrombotic events or clinical background, might be associated with higher risk of in-hospital mortality. Moreover, AKI, age, lymphocyte count, and cardiovascular disease may represent important risk factors that could help identify at-risk patients who require long-term hospitalization with therapeutic dose AC treatment. Public Library of Science 2022-01-19 /pmc/articles/PMC8769345/ /pubmed/35045130 http://dx.doi.org/10.1371/journal.pone.0262811 Text en © 2022 Hoogenboom et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hoogenboom, Wouter S.
Lu, Joyce Q.
Musheyev, Benjamin
Borg, Lara
Janowicz, Rebeca
Pamlayne, Stacey
Hou, Wei
Duong, Tim Q.
Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19
title Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19
title_full Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19
title_fullStr Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19
title_full_unstemmed Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19
title_short Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19
title_sort prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with covid-19
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769345/
https://www.ncbi.nlm.nih.gov/pubmed/35045130
http://dx.doi.org/10.1371/journal.pone.0262811
work_keys_str_mv AT hoogenboomwouters prophylacticversustherapeuticdoseanticoagulationeffectsonsurvivalamongcriticallyillpatientswithcovid19
AT lujoyceq prophylacticversustherapeuticdoseanticoagulationeffectsonsurvivalamongcriticallyillpatientswithcovid19
AT musheyevbenjamin prophylacticversustherapeuticdoseanticoagulationeffectsonsurvivalamongcriticallyillpatientswithcovid19
AT borglara prophylacticversustherapeuticdoseanticoagulationeffectsonsurvivalamongcriticallyillpatientswithcovid19
AT janowiczrebeca prophylacticversustherapeuticdoseanticoagulationeffectsonsurvivalamongcriticallyillpatientswithcovid19
AT pamlaynestacey prophylacticversustherapeuticdoseanticoagulationeffectsonsurvivalamongcriticallyillpatientswithcovid19
AT houwei prophylacticversustherapeuticdoseanticoagulationeffectsonsurvivalamongcriticallyillpatientswithcovid19
AT duongtimq prophylacticversustherapeuticdoseanticoagulationeffectsonsurvivalamongcriticallyillpatientswithcovid19